Technology appraisal guidance [TA70] Published date: 22 October 2003 Last updated: 21 January 2016
The Institute issued guidance on the use of imatinib for people with CML in the chronic phase after failure of IFN-α, in the accelerated phase and in blast crisis in October 2002, which is now replaced by this current guidance.